Insights into the conformational switching mechanism of the human vascular endothelial growth factor receptor type 2 kinase domain
- PMID: 22229497
- DOI: 10.1021/ci200513a
Insights into the conformational switching mechanism of the human vascular endothelial growth factor receptor type 2 kinase domain
Abstract
Human vascular endothelial growth factor receptor type 2 (h-VEFGR2) is a receptor tyrosine kinase involved in the angiogenesis process and regarded as an interesting target for the design of anticancer drugs. Its activation/inactivation mechanism is related to conformational changes in its cytoplasmatic kinase domain, involving first among all the αC-helix in N-lobe and the A-loop in C-lobe. Affinity of inhibitors for the active or inactive kinase form could dictate the open or closed conformation of the A-loop, thus making the different conformations of the kinase domain receptor (KDR) domain different drug targets in drug discovery. In this view, a detailed knowledge of the conformational landscape of KDR domain is of central relevance to rationalize the efficiency and selectivity of kinase inhibitors. Here, molecular dynamics simulations were used to gain insight into the conformational switching activity of the KDR domain and to identify intermediate conformations between the two limiting active and inactive conformations. Specific energy barriers have been selectively removed to induce, and hence highlight at the atomistic level, the regulation mechanism of the A-loop opening. The proposed strategy allowed to repeatedly observe the escape of the KDR domain from the DFG-out free energy basin and to identify rare intermediate conformations between the DFG-out and the DFG-in structures to be employed in a structure-based drug discovery process.
Similar articles
-
Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.J Mol Graph Model. 2009 Jan;27(5):642-54. doi: 10.1016/j.jmgm.2008.10.006. Epub 2008 Nov 5. J Mol Graph Model. 2009. PMID: 19081278
-
Development and strategies of VEGFR-2/KDR inhibitors.Future Med Chem. 2012 Sep;4(14):1839-52. doi: 10.4155/fmc.12.121. Future Med Chem. 2012. PMID: 23043480 Review.
-
Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region.Biochem J. 2008 May 1;411(3):515-22. doi: 10.1042/BJ20080078. Biochem J. 2008. PMID: 18251716
-
3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.J Mol Graph Model. 2007 Jul;26(1):236-45. doi: 10.1016/j.jmgm.2006.12.001. Epub 2006 Dec 8. J Mol Graph Model. 2007. PMID: 17293140
-
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.Curr Opin Drug Discov Devel. 2004 Sep;7(5):639-48. Curr Opin Drug Discov Devel. 2004. PMID: 15503866 Review.
Cited by
-
Discovery of Novel Multiangiogenic Agents Targeting VEGFR2, EphB4, FGFR-1, and TIE-2: Receptor-Based Pharmacophore Modeling, Virtual Screening, and Molecular Modeling Studies.ACS Omega. 2025 Apr 1;10(14):13880-13897. doi: 10.1021/acsomega.4c08366. eCollection 2025 Apr 15. ACS Omega. 2025. PMID: 40256504 Free PMC article.
-
Multiple steps to activate FAK's kinase domain: adaptation to confined environments?Biophys J. 2013 Jun 4;104(11):2521-9. doi: 10.1016/j.bpj.2013.04.021. Biophys J. 2013. PMID: 23746525 Free PMC article.
-
Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.Sci Rep. 2017 Mar 23;7:45145. doi: 10.1038/srep45145. Sci Rep. 2017. PMID: 28332573 Free PMC article.
-
Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase.ACS Med Chem Lett. 2013 Jun 24;4(8):736-41. doi: 10.1021/ml400145x. eCollection 2013 Aug 8. ACS Med Chem Lett. 2013. PMID: 24900740 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources